Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 3/20 | 0.38 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F5 | P12259 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207922 | 0.89 | ALDH1A1 (0.44) | IDO1TDO2CCR1TSHRF10 | |
| SCHEMBL210778 | 0.89 | IDO1 (0.42) | IDO1PTK2TDO2CCR1TSHR | |
| SCHEMBL206636 | 0.88 | IDO1 (0.41) | IDO1TDO2CCR1F10EIF2AK4 | |
| SCHEMBL4267730 | 0.87 | IDO1 (0.39) | IDO1TDO2CCR1TSHRF10 | |
| SCHEMBL4267724 | 0.87 | IDO1 (0.39) | IDO1TDO2CCR1TSHRF10 | |
| SCHEMBL208363 | 0.86 | F10 (0.42) | IDO1PTK2TDO2CCR1TSHR | |
| SCHEMBL209753 | 0.86 | IDO1 (0.40) | IDO1PTK2TDO2CCR1TSHR | |
| SCHEMBL209026 | 0.85 | IDO1 (0.37) | IDO1TDO2CCR1TSHRF10 | |
| SCHEMBL4269427 | 0.85 | IDO1 (0.38) | IDO1TDO2CCR1TSHRF10 | |
| SCHEMBL4269421 | 0.85 | IDO1 (0.38) | IDO1TDO2CCR1TSHRF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1864982-A1 | TRIAMINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239857-A1 | TRIAMINE DERIVATIVE | F2, F12, F3 | IDO1 569/4885PTK2 627/4885TDO2 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.